

1 **Clinical outcomes after the introduction of dolutegravir for second-line antiretroviral**
2 **therapy in South Africa: a retrospective cohort study**

3

4 **Authors:** Kwabena Asare^{1,5}, Yuktेशwar Sookrajh², Johan van der Molen¹, Thokozani
5 Khubone², Lara Lewis¹, Richard J Lessells^{1,3}, Kogieleum Naidoo^{1,4}, Phelelani Sosibo²,
6 Rosemary van Heerden², Nigel Garrett^{1,5} and Jienchi Dorward^{1,6}

7

8 **Institutions**

- 9 1. Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South
10 Africa
- 11 2. eThekweni Municipality Health Unit, eThekweni Municipality, Durban KwaZulu-Natal,
12 South Africa
- 13 3. KwaZulu-Natal Research and Innovation Sequencing Platform (KRISP), University of
14 KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa
- 15 4. South African Medical Research Council (SAMRC)-CAPRISA-TB-HIV Pathogenesis and
16 Treatment Research Unit, University of KwaZulu-Natal Nelson R Mandela School of
17 Medicine, Durban, South Africa
- 18 5. Discipline of Public Health Medicine, School of Nursing and Public Health, University of
19 KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa
- 20 6. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxfordshire,
21 United Kingdom

22

23 **Corresponding author:** Mr Kwabena Asare, MSc. Centre for the AIDS Programme of Research
24 in South Africa. Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine,
25 University of KwaZulu-Natal, Private Bag X7, Congella, 4013, South Africa. Telephone: +27 31
26 260 4453; E-mail: kwabena.asare@caprisa.org

27 **Email addresses of authors**

28 YS: yukteshwar.sookrajh@durban.gov.za

29 JvM: johan.molen@caprisa.org

30 TK: thokozani.32khubone@durban.gov.za

31 LL: lara.lewis@caprisa.org

32 RJL: lessellsr@ukzn.ac.za

33 KN: kogie.naidoo@caprisa.org

34 PS: cedrick.sosibo@durban.gov.za

35 RvH: rosemary.vanheerden@durban.gov.za

36 NG: nigel.garrett@caprisa.org

37 JD: jienchi.dorward@phc.ox.ac.uk

38

39 **Keywords:** HIV, anti-retroviral therapy, dolutegravir, lopinavir-ritonavir, retention-in-care,
40 second-line treatment, viral suppression.

41

42 **ABBREVIATIONS**

43 ART: Anti-retroviral therapy

44 RD: Risk difference

45 RR: Risk Ratio

46 LMIC: Low- and Middle-Income Country

47 PLHIV: People living with HIV

48 WHO: World Health Organization

49

50 **WORD COUNT:**

51 Abstract 296/300, Main Body 3398/3500

52

53 **Target Journal:** Lancet HIV

54

55 **ABSTRACT**

56 **Background.** Dolutegravir is now recommended for second-line anti-retroviral therapy (ART) in
57 low- and middle-income countries. We compared outcomes with dolutegravir (DTG) versus the
58 previous lopinavir/ritonavir (LPV/r) regimen in South Africa.

59 **Methods.** We used routinely collected, de-identified data from 59 South African clinics. We
60 included people living with HIV aged ≥ 15 years with virologic failure (two consecutive viral
61 loads ≥ 1000 copies/mL) on first-line tenofovir disoproxil fumarate (TDF)-based ART and
62 switched to second-line ART. We used modified Poisson regression models to compare outcomes
63 of 12-month retention-in-care and viral suppression (< 50 copies/ml) after switching to second-
64 line regimens of zidovudine (AZT), emtricitabine/lamivudine (XTC), DTG and TDF/XTC/DTG
65 and AZT/XTC/LPV/r.

66 **Findings.** Of 1214 participants, 729 (60.0%) were female, median age was 36 years
67 (interquartile range 30 to 42), 689 (56.8%) were switched to AZT/XTC/LPV/r, 217 (17.9%) to
68 AZT/XTC/DTG and 308 (25.4%) to TDF/XTC/DTG. Retention-in-care was higher with
69 AZT/XTC/DTG (85.7%, adjusted risk ratio (aRR) 1.14, 95% confidence interval (CI) 1.03 to
70 1.27; adjusted risk difference (aRD) 10.89%, 95%CI 2.01 to 19.78) but not different with
71 TDF/XTC/DTG (76.9%, aRR 1.01, 95%CI 0.94 to 1.10; aRD 1.04%, 95%CI -5.03 to 7.12)
72 compared to AZT/XTC/LPV/r (75.2%). Retention-in-care with TDF/XTC/DTG was not
73 statistically significantly different from AZT/XTC/DTG (aRR 0.89, 95%CI 0.78 to 1.01; aRD -
74 9.85%, 95%CI -20.33 to 0.63). Of 799 participants who were retained-in-care with a 12-month
75 viral load, viral suppression was higher with AZT/XTC/DTG (59.3%, aRR 1.25, 95%CI 1.06 to
76 1.47; aRD 11.57%, 95%CI 2.37 to 20.76) and TDF/XTC/DTG (60.7%, aRR 1.30, 95%CI 1.14 to
77 1.48; aRD 14.16%, 95%CI 7.14 to 21.18) than with the AZT/XTC/LPV/r regimen (46.7%).

78 **Interpretation.** DTG-based second-line regimens were associated with similar or better
79 retention-in-care and better viral suppression than the LPV/r-based regimen. TDF/XTC/DTG had
80 similar viral suppression compared to AZT/XTC/DTG.

81 **Funding.** Bill & Melinda Gates Foundation, Africa Oxford Initiative.

82 RESEARCH IN CONTEXT

83 Evidence before this study

84 We searched PubMed from inception until May 30, 2023, with no language restrictions, for
85 published articles evaluating outcomes with dolutegravir-zidovudine-based versus dolutegravir-
86 tenofovir disoproxil fumarate-based versus lopinavir-ritonavir-based regimens for second-line
87 anti-retroviral therapy. We used search words [dolutegravir AND (tenofovir OR lopinavir-
88 ritonavir) AND (second-line anti-retroviral therapy)]. We found 5 clinical trials (DAWNING,
89 NADIA, D2EFT, VISEND and ARTIST) and zero observational studies. The DAWNING trial
90 showed the superiority of dolutegravir versus ritonavir-boosted lopinavir, when used with two
91 nucleoside reverse transcriptase inhibitors (NRTIs) in 624 participants with previous first-line
92 failure (≥ 400 copies/ml) with non-nucleoside reverse transcriptase inhibitor (NNRTI) based
93 regimens. At week 48 after baseline, 261 of 312 (84.0%) participants in the dolutegravir group
94 achieved viral suppression (< 50 copies/ml) compared with 219 of 312 (70.0%) in the ritonavir-
95 boosted lopinavir group. Among 464 participants in the NADIA trial with first-line treatment
96 failure (≥ 1000 copies/ml) on an NNRTI with tenofovir and lamivudine or emtricitabine,
97 recycled tenofovir for second-line treatment was non-inferior at week 48 compared to zidovudine
98 (90.2% vs 91.7%) all used with dolutegravir or darunavir for viral suppression (< 400 copies/ml).
99 The VISEND and D2EFT trials demonstrated the non-inferiority of dolutegravir with tenofovir
100 and lamivudine or emtricitabine to standard-of-care ritonavir-boosted protease inhibitors
101 lopinavir, atazanavir and darunavir for second-line treatment. In the single-arm ARTIST trial,
102 including 62 participants with virologic failure on first-line tenofovir and lamivudine or
103 emtricitabine with efavirenz or nevirapine and switched to second-line regimens with recycled
104 tenofovir and dolutegravir, viral suppression (< 50 copies/ml) was 74.0% at 48 weeks. These
105 clinical trials, except the ARTIST trial, have demonstrated the effectiveness of second-line DTG
106 used with AZT or recycled first-line tenofovir for viral suppression compared to previous
107 standard-of-care ritonavir-boosted protease inhibitor-based regimens. However, outcomes in
108 non-trial or routine healthcare settings, where treatment adherence might be relatively lower than
109 in trial settings, are scarce. Furthermore, the relative effectiveness of these second-line regimens
110 on retention-in-care, probably due to regimen tolerability within an anti-retroviral treatment
111 programme setting, is also limited.

112

113 **Added value of this study**

114 After the implementation of dolutegravir for second-line anti-retroviral treatment in low- and
115 middle-income countries, this is the first study using ART programme data from routine care
116 clinics to assess outcomes after switching to second-line dolutegravir used with zidovudine or
117 recycled first-line tenofovir versus the previously recommended ritonavir-boosted lopinavir on
118 12-month retention-in-care and viral suppression. Dolutegravir was better when used with
119 zidovudine but was similar when used with recycled tenofovir for retention-in-care, and all were
120 better for viral suppression versus the previous ritonavir-lopinavir-based regimen. Dolutegravir
121 used with recycled tenofovir was slightly lower but not significantly different for retention-in-
122 care and similar for viral suppression versus when used with the standard zidovudine.

123

124 **Implications of all the available evidence**

125 Evidence from ongoing real-world cohorts through anti-retroviral treatment programmatic data
126 evaluation is important for confirming the usefulness of common regimen combinations in
127 regular healthcare settings to guide further decision-making. We have provided evidence outside
128 clinical trial settings supporting WHO's recommendation of dolutegravir use replacing lopinavir-
129 ritonavir for second-line treatment in resource-limited settings. Our findings also suggest that
130 recycling first-line tenofovir instead of replacing it with zidovudine for a dolutegravir-based
131 second-line regimen can be an effective alternative for viral suppression. Further evidence from
132 routine care settings on adverse events during second-line dolutegravir-based treatment would be
133 a vital addition to evidence for continuous improvement of anti-retroviral treatment guidelines.

134 **INTRODUCTION**

135 Following World Health Organization (WHO)^{1,2} recommendations, dolutegravir (DTG) has been
136 implemented for second-line antiretroviral therapy (ART) in South Africa since December 2019,
137 replacing previously recommended regimens with lopinavir-ritonavir (LPV/r)^{3,4}. The WHO
138 recommendation was based on results from the DAWNING trial⁵ showing superior efficacy of
139 DTG for second-line ART compared to LPV/r. Furthermore, evidence from the NADIA⁶ trial
140 suggested that recycling or maintaining first-line tenofovir disoproxil fumarate (TDF) in a DTG-
141 based second-line ART was non-inferior to switching to Zidovudine (AZT). However, there is
142 little data from routine care demonstrating the effectiveness of DTG, either with AZT or
143 recycling TDF, on clinical outcomes during second-line ART.

144 Before December 2019, people living with HIV (PLHIV) in South Africa who were receiving the
145 standard first-line regimen of TDF, emtricitabine (FTC) and efavirenz (EFV), and presented with
146 virologic failure (repeat viral load \geq 1000 copies/ml two to three months apart), were
147 recommended to switch to second-line regimen of zidovudine (AZT), lamivudine (3TC) and
148 LPV/r.⁴ After DTG was introduced for second-line ART in 2019, they were recommended to
149 switch to AZT/3TC/DTG. Some people with virologic failure during first-line treatment may
150 have been switched to TDF/3TC/DTG, either inadvertently as part of the transition to first-line
151 dolutegravir or by clinicians following preliminary evidence suggesting that TDF/3TC/DTG may
152 be an effective second-line regimen.⁷ As the rollout of DTG in low- and middle-income countries
153 (LMICs) continues^{8,9}, evidence on the effectiveness of different regimens in routine care settings
154 is required to guide further rollout and confirm clinical trial findings.⁷

155 Therefore, we aimed to evaluate the effectiveness of DTG plus emtricitabine/lamivudine (XTC)
156 in combination with AZT or TDF versus the previously recommended regimen AZT/XTC/LPV/r
157 for second-line treatment in routine care settings.

158 **METHODS**

159 **Study design and setting**

160 We did a retrospective cohort study with de-identified, routinely collected data from South
161 Africa's ART program in 59 primary healthcare facilities in the eThekweni Municipality of the
162 KwaZulu-Natal province. South Africa's ART delivery in public healthcare clinics involves
163 clinical assessment for pregnancy, viral load, and CD4 count testing and screening for
164 tuberculosis at baseline ART initiation and follow-up visits.⁴ Viral load is repeated at 6 and 12
165 months after ART initiation and 12-monthly thereafter. CD4 count is measured at ART initiation
166 and 12 months thereafter and then only repeated if clinically indicated (e.g., viral load ≥ 1000
167 copies/ml). PLHIV with a viral load ≥ 1000 copies/ml are recommended to receive enhanced
168 adherence counselling and a repeat viral load after two to three months. For people receiving
169 first-line regimens containing a non-nucleoside reverse transcriptase inhibitor (NNRTI) such as
170 efavirenz or nevirapine, virological failure is defined as two consecutive viral loads ≥ 1000
171 copies/ml two to three months apart and switching to second-line ART is recommended. There is
172 no routine HIV drug resistance testing at the time of first-line ART failure in this setting. The
173 study was approved by the Biomedical Research Ethics Committee of the University of
174 Kwazulu-Natal (BE646/17), the KwaZulu-Natal Provincial Health Research Ethics Committee
175 (KZ_201807_021), the TB/HIV Information Systems Data Request Committee, and the
176 eThekweni Municipality Health Unit.

177 **Participants**

178 Our study population included all PLHIV aged ≥ 15 who were switched to a second-line ART
179 regimen between December 1, 2019, and November 30, 2020. We used this baseline period of
180 second-line switching to allow a minimum of 12 months follow-up duration plus 180 days before
181 the data cutoff on April 21, 2022. We excluded people not previously receiving standard first-line
182 regimens of TDF/XTC/EFV or TDF/XTC/NVP at the time of virologic failure and those not
183 switched to second-line regimens of AZT/XTC/LVP/r, AZT/XTC/DTG and TDF/XTC/DTG.
184 Thus, we excluded people who were switched to a four-drug regimen of AZT/3TC/TDF plus
185 LPV/r or DTG (i.e. hepatitis B coinfecting participants) and those switched to abacavir-based
186 regimens. We also excluded people who did not strictly meet guideline-defined first-line
187 virologic failure criteria (two consecutive viral loads ≥ 1000 copies/ml at least 56 days apart).

188 **Data sources and data management**

189 We used data from South Africa's TIER.Net electronic database, which contains demographics,
190 clinical status, regimen and clinic visit information of people receiving ART in public sector
191 healthcare clinics.¹⁰ Data were de-identified by the South African National Department of
192 Health's TB/HIV Information Systems (THIS -www.tbhivinfosys.org.za/) before access and
193 analysis by the study team.

194 **Outcomes**

195 Our primary outcomes were retention-in-care and viral suppression at 12 months after starting
196 second-line treatment. Retention-in-care at 12 months was defined as not being lost to follow-up
197 or recorded in TIER.Net as either deceased or 'transferred out' to another clinic (as we could not
198 access or link to data at other clinics to establish retention-in-care) by 365 days after starting
199 second-line treatment. We defined loss to follow-up using the South African ART programme
200 guidelines of being 90 days late for a visit¹¹ and used the date of last visit as the date of loss-to-
201 follow-up. Viral suppression was defined as viral load < 50 copies/ml. We included one
202 secondary outcome for a post-hoc sensitivity analysis defining viral suppression as viral load <
203 1000 copies/ml. Because viral loads are not always completed regularly in routine care, we
204 defined the 12-month window as the closest viral load to 365 days between 181 to 545 days after
205 starting second-line treatment and included only the viral loads of participants retained in care.

206 **Exposures**

207 The primary exposure was the second-line ART regimen combination (AZT/XTC/DTG or
208 TDF/XTC/DTG or AZT/XTC/LPV/r) that participants were switched to after virologic failure.
209 Secondary exposures included participant baseline characteristics when starting second-line
210 treatment, such as age, gender, active tuberculosis, most recent viral load, most recent CD4
211 count, and time on ART.

212 **Statistical analyses**

213 We performed all statistical analyses using R 4.2.0 (R Foundation for Statistical Computing,
214 Vienna, Austria)¹² and STATA 17.0¹³. We summarised participants' baseline demographic,
215 clinical characteristics, and outcomes at 12 months follow-up. We used percentages and medians
216 to describe the baseline characteristics and assessed missing data stratified by the second-line
217 regimen. We conducted univariable and multivariable modified Poisson regression with robust

218 standard errors adjusting for clustering by clinic¹⁴ to determine the risk ratios of retention-in-care
219 and viral suppression at 12 months follow-up. In all regression analyses, we compared the two
220 DTG-based regimens of AZT/XTC/DTG and TDF/XTC/DTG versus AZT/XTC/LPV/r that
221 participants were originally prescribed when starting second-line treatment and reported the risk
222 differences. We also present results from these models comparing TDF/XTC/DTG versus
223 AZT/XTC/DTG. We adjusted for participant characteristics at baseline, namely age category,
224 gender, active tuberculosis, and category for recent viral load, in the multivariable regression
225 models. We did not include the most recent CD4 count or time on ART in the multivariable
226 models, as the resultant predicted probabilities exceeded one. Instead, we conducted sensitivity
227 analyses of the effect of the ART regimen on each outcome, adjusted for only CD4 count and
228 time on ART, to demonstrate a lack of confounding by these variables. We conducted further
229 sensitivity analyses excluding participants who changed their originally prescribed second-line
230 regimen within 12 months after baseline.

231 **Role of the funding source**

232 The study's funders played no role in this article's study design, data collection, analysis,
233 interpretation, or writing.

234 **RESULTS**

235 From December 1, 2019, to November 30, 2020, 1672 people were recorded as switching to
236 second-line ART after virologic failure (two consecutive viral loads ≥ 1000 copies/ml at least 56
237 days apart) while receiving first-line ART at the study clinics (Figure 1). We excluded 302
238 participants who were not previously receiving standard first-line regimens of TDF/XTC/EFV or
239 TDF/XTC/NVP at the time of virologic failure and 156 who were not switched to standard
240 second-line regimens of AZT/XTC/LPV/r or AZT/XTC/DTG or TDF/XTC/DTG. Of the
241 remaining 1214 participants who were included in this analysis, 689 (56.8 %) were switched to
242 AZT/XTC/LPV/r, 217 (17.9%) were switched to AZT/XTC/DTG, and 308 (25.4%) were
243 switched to TDF/XTC/DTG second-line regimens.

244 Overall, the median age was 36 (interquartile range (IQR) 30-42), and 60.0% (n = 729) were
245 female (Table 1). Almost all participants previously received first-line TDF/XTC/EFV (n = 1198,
246 98.7%). Age was similar between the three regimen groups, but there were more females in the
247 AZT/XTC/LPV/r group (n = 460, 66.8%) than in the AZT/XTC/DTG (n = 108, 49.8%) and

248 TDF/XTC/DTG (n = 161, 52.3%) groups. The TDF/XTC/DTG group had more participants (n =
249 155, 50.3%) with recent viral load at baseline < 10,000 copies/ml than the AZT/XTC/DTG (n =
250 80, 36.9%) and AZT/XTC/LPV/r (n = 260, 37.7%) groups. Time from most recent viral load to
251 second-line switch was a median (IQR) of 50 days (28, 95) in the AZT/XTC/LPV/r group, 49
252 days (28, 102) in the AZT/XTC/DTG group and 34 days (0, 79) in the TDF/XTC/DTG group. A
253 higher proportion of participants in the AZT/XTC/LPV/r (n = 264, 38.3%) and AZT/XTC/DTG
254 (n = 94, 43.3%) groups had the most recent CD4 count \leq 200 cells/ μ L, compared to the
255 TDF/XTC/DTG group (n = 79, 25.6%).

256 During follow-up, 10.0% (n = 121) changed their originally prescribed second-line regimen after
257 a median of 158 days, IQR (84, 234) (Table 2). By 12 months, 941 (77.5%) were retained-in-
258 care, 80 (6.6%) had transferred out to another clinic, 16 (1.3%) were known to have died, and
259 177 (14.6%) were lost to follow-up. Retention-in-care at 12 months was 75.2% (n = 518) in
260 participants receiving AZT/XTC/LPV/r, 85.7% (n = 186) in those receiving AZT/XTC/DTG and
261 76.9% (n = 237) in those receiving TDF/XTC/DTG (Table 3). After adjusting for potential
262 confounders, retention-in-care at 12 months was more likely in participants receiving
263 AZT/XTC/DTG (adjusted risk ratio [aRR] 1.14, 95% CI 1.03 to 1.27, p = 0.012; adjusted risk
264 difference [aRD] 10.89%, 95% CI 2.01 to 19.78, p = 0.016) than those receiving
265 AZT/XTC/LPV/r. Retention-in-care at 12 months was not different in participants receiving
266 TDF/XTC/DTG (aRR 1.01, 95% CI 0.94 to 1.10, p = 0.733; aRD 1.04%, 95% CI -5.03 to 7.12, p
267 = 0.736) compared to those receiving AZT/XTC/LPV/r. Retention-in-care at 12 months was
268 lower in participants receiving TDF/XCT/DTG (76.9%) than AZT/XTC/DTG (85.7%), but the
269 difference was not statistically significant (aRR 0.89, 95% CI 0.78 to 1.01, p = 0.060; aRD -
270 9.85%, 95% CI -20.33 to 0.63, p = 0.066).

271 Of 941 participants who were retained in care at 12 months, 799 (84.9%) had a viral load done at
272 a median of 357 days, IQR (293-418) (Table 2). By regimen, 448 (86.5%) of those receiving
273 AZT/XTC/LPV/r, 150 (80.6%) of those receiving AZT/XTC/DTG and 201 (84.8%) of those
274 receiving TDF/XTC/DTG had a viral load done at 12 months follow-up. Of participants with a
275 viral load at 12 months, viral suppression (< 50 copies/ml) was higher in those receiving
276 AZT/XTC/DTG (n = 89, 59.3%) and TDF/XTC/DTG (n = 122, 60.7%) than AZT/XTC/LPV/r (n
277 = 209, 46.7%). Viral suppression (< 50 copies/ml) at 12 months was more likely in participants

278 receiving AZT/XTC/DTG (aRR 1.25, 95% CI 1.06 to 1.47, $p = 0.009$; aRD 11.57%, 95% CI 2.37
279 to 20.76, $p = 0.014$) and TDF/XTC/DTG (aRR 1.30, 95% CI 1.14 to 1.48, $p < 0.001$; aRD
280 14.16%, 95% CI 7.14 to 21.18, $p < 0.001$) than participants receiving AZT/XTC/LPV/r (Table
281 4). Viral suppression (< 50 copies/ml) at 12 months was similar in participants receiving
282 TDF/XCT/DTG compared to AZT/XTC/DTG (aRR 1.04, 95% CI 0.88 to 1.24, $p = 0.624$; aRD
283 2.59%, 95% CI -7.78 to 12.60, $p = 0.624$). In a post-hoc sensitivity analysis presented as part of
284 the supplementary results, viral suppression (< 1000 copies/ml) at 12 months was more likely in
285 participants receiving AZT/XTC/DTG (86.0%, aRR 1.19, 95% CI 1.07 to 1.32, $p = 0.001$; aRD
286 13.22%, 95% CI 5.02 to 21.41, $p = 0.002$) and TDF/XTC/DTG (78.1%, aRR 1.11, 95% CI 1.01
287 to 1.22, $p = 0.033$; aRD 7.63%, 95% CI 0.50 to 14.77, $p = 0.036$) than participants receiving
288 AZT/XTC/LPV/r (69.4%) (Table S 1). Viral suppression (< 1000 copies/ml) at 12 months was
289 similar in participants receiving TDF/XCT/DTG compared to AZT/XTC/DTG (aRR 0.93, 95%
290 CI 0.85 to 1.02, $p = 0.143$; aRD -5.58%, 95% CI -13.12 to 1.95, $p = 0.146$).

291 The supplementary results (Tables S2, S3, and S4) showed no significant confounding of
292 retention-in-care and viral suppression outcomes by recent baseline CD4 count and time on ART
293 at baseline. In Tables S5, S6 and S7, results show that retention-in-care and viral suppression
294 outcomes were consistent with the main analysis after excluding participants who changed their
295 originally prescribed second-line regimen within 12 months after baseline.

296 **DISCUSSION**

297 In this retrospective cohort study with routine data from 59 clinics in South Africa, compared to
298 second-line LPV/r-based regimens, second-line DTG-based regimens were associated with
299 similar or better retention in care and better viral suppression. We did not find evidence of a
300 significant difference in retention or viral suppression between TDF/XTC/DTG and
301 AZT/XTC/DTG.

302 We evaluated retention-in-care at 12 months because drug tolerability is known to influence
303 adherence¹⁵ and retention-in-care¹⁶. We saw higher retention-in-care with AZT/XTC/DTG than
304 AZT/XTC/LPV/r consistent with the favourable safety profile of DTG-based versus LPV/r-based
305 regimens for second-line treatment in the DAWNING trial⁵ and generally reported during first-
306 line treatment^{5,17-19}. Retention-in-care with TDF/XTC/DTG (76.9%) was lower than with
307 AZT/XTC/DTG (85.7%) although not significantly different (P value = 0.066), but we expected

308 similar rates as TDF is slightly more tolerable than AZT^{20,21}. The week-96 results of the NADIA
309 trial²² showed identical low rates of adverse events leading to second-line treatment
310 discontinuation in the TDF-based (n = 2, 1.0%) and the AZT-based (n = 3, 1.0%) groups.

311 The DAWNING trial is the only clinical trial directly comparing the efficacy of DTG versus
312 LPV/r for second-line ART. The trial enrolled 624 PLHIV \geq 18 years with virologic failure
313 during first-line treatment and randomized 312 to receive DTG and 312 to receive LPV/r in a
314 second-line regimen plus two NRTIs, with at least one being fully active.⁵ Most participants in
315 the DTG-based group reported high ART adherence scores and lower treatment-related adverse
316 events (67.0% and 16.0%) compared to the LPV/r group (56.0% and 38.0%).⁵ There were also
317 fewer adverse events leading to treatment discontinuation in the DTG group (3.0%) than the
318 LPV/r group (6.0%), which may explain the improved retention-in-care that we found with
319 AZT/XTC/DTG versus AZT/XTC/LPV/r.⁵ In the primary intention to treat analysis, the primary
320 outcome of viral suppression (viral load < 50 copies/ml) at 48 weeks was higher in the DTG
321 group (84.0%) compared to the LPV/r group (70.0%), adjusted difference 13.8%; 95% CI 7.3 to
322 20.3.⁵

323 There are four clinical trials assessing the efficacy of recycling TDF in a second-line regimen.
324 The NADIA trial used a 2 x 2 factorial design to randomise PLHIV with virologic failure during
325 first-line treatment to receive second-line dolutegravir or lopinavir-boosted darunavir and either
326 tenofovir or zidovudine.⁶ Recycling tenofovir for second-line treatment was non-inferior to
327 switching to zidovudine for viral suppression (viral load < 400 copies/ml) at 48 weeks.⁶

328 Consistent with results from the NADIA trial, we found no difference between TDF/XTC/DTG
329 versus AZT/XTC/DTG for viral suppression at < 50 copies/ml. The smaller single-arm ARTIST
330 trial in 62 participants showed 74.0% viral suppression (< 50 copies/ml) at 48 weeks with
331 TDF/XTC/DTG during second-line treatment.^{23,24} Preliminary results from the VISEND²⁵ and
332 D2EFT²⁶ trials also found TDF/XTC/DTG as non-inferior to ritonavir-boosted lopinavir or
333 atazanavir (VISEND) and darunavir (D2FT). In this routine care setting, TDF/XTC/DTG was
334 associated with better viral suppression versus AZT/XTC/LPV/r.

335 Viral suppression rates are generally higher in these trials than we found in routine care, probably
336 due to better treatment adherence and monitoring^{27,28} among participants in clinical trials²⁹. But
337 differences in cohort baseline virologic failure and post-baseline viral suppression thresholds

338 might also be responsible for the different outcomes. Although the DAWNING⁵ trial used a viral
339 suppression of < 50 copies/ml, it included participants with a baseline viral load between 400 to
340 < 1000 copies/ml (9.0% in the DTG group, 11.0% in the LPV/r group) versus our cohort which
341 used a guideline-defined threshold of \geq 1000 copies/ml. The NADIA⁶ trial used a baseline viral
342 load of \geq 1000 copies/ml as we did but defined viral suppression at < 400 copies/ml. The
343 VISEND²⁵ trial included participants with a baseline viral load of \geq 1000 copies/ml and used a
344 viral suppression threshold of < 1000 copies/ml. The resulting viral suppression < 1000
345 copies/ml at 12 months (82.0% with TDF/XTC/DTG and 76.0% with AZT/3TC plus LPV/r or
346 atazanavir/r)²⁵ was similar to what we found in post-hoc sensitivity analyses with same
347 thresholds (78.1% with TDF/XTC/DTG, 69.4% with AZT/XTC/LPV/r and 86.0% with
348 AZT/XTC/DTG). A multisite cohort study conducted between 2007 to 2009 in 6 African
349 countries, including South Africa, reported 13.9% virologic failure (\geq 400 copies/ml) at 12
350 months after starting second-line treatment with protease-inhibitor-based regimens, which we
351 interpret as 86.1% viral suppression (< 400 copies/ml).²⁷

352 Overall, outcomes were poor in this cohort of people switching to second-line ART after first-
353 line virologic failure in routine care. Of the 1214 people, just about a third, 420 (34.6%),
354 achieved programmatic retention-in-care and viral suppression milestones at 12 months. This
355 highlights the need to improve other outcomes in the care cascade in ART programmes during
356 second-line treatment, particularly adherence counselling, as regimen choice is only one factor
357 necessary for improving HIV treatment outcomes.

358 Our findings are among the first evidence of outcomes with two common dolutegravir-based
359 regimen combinations for second-line ART in resource-limited routine healthcare settings. We
360 used guideline-defined virologic failure, viral suppression, and retention-in-care and adjusted for
361 the effects of baseline characteristics when switching to second-line treatment. Our findings
362 support WHO's recommendation of dolutegravir for second-line ART in adults with treatment
363 failure on a first-line regimen containing an NNRTI such as nevirapine or efavirenz.¹

364 Furthermore, WHO recommends the substitution of TDF, a common drug in most first-line
365 regimens in LMICs, with zidovudine when switching to second-line treatment to ensure having
366 an active NRTI backbone due to limited resistance testing³⁰ for selecting appropriate NRTIs.^{1,2}
367 However, based on results from the NADIA trial suggesting the non-inferiority of recycling TDF

368 instead of switching to AZT, and the availability of TLD as a fixed dose combination,
369 TDF/XTC/DTG is considered an easily implementable regimen.⁷ Our findings have provided
370 further assurance regarding these assertions with evidence from routine care that recycled TDF in
371 a second-line DTG-based regimen can result in similar viral suppression <50 copies/ml at 12
372 months as with switching to AZT, both of which can be more effective than the previous regimen
373 of AZT/XTC/LPV/r. This finding is, therefore, also relevant to other resource-limited settings
374 where resistance testing is not routinely done to guide the selection of NRTIs for second-line
375 treatment.

376 Our analysis had some potential limitations. First, we used data from only one district in South
377 Africa, which might have limited the generalizability of the findings, however, the sample size
378 was large considering the high HIV burden in our setting. Second, we only assessed 12-month
379 outcomes, and evaluating longer-term follow-up will be important in future analyses. Third,
380 although we adjusted for the most relevant baseline characteristics, we cannot rule out potential
381 unmeasured confounders. Fourth, we were unable to include the recent CD4 count and time on
382 ART in the multivariable analysis as it led to overfitted models with predicted probabilities
383 exceeding one. We, therefore, evaluated the impact of baseline CD4 count and years on ART in
384 supplementary analyses, which showed no evidence of significant confounding of the primary
385 outcomes. Fifth, in a new era of DTG, clinicians and nurses might have selected specific PLHIV
386 for DTG treatment who were more likely to have better outcomes. Furthermore, people who
387 received TDF/XTC/DTG after virological failure may have been put on this regimen in error as
388 part of the transition to first-line dolutegravir or were more likely to be anaemic, a
389 contraindication to AZT⁴. They may, therefore, not have received similar treatment to those
390 receiving the recommended second-line regimens (for example, they may not have received
391 enhanced adherence counselling), which could make them different from the AZT groups
392 introducing further bias. Furthermore, we do not have follow-up measures of regimen-related
393 adverse events for comparison, but the DAWNING trial⁵ showed a favourable safety profile with
394 DTG than LPV/r during second-line ART, and the NADIA trial showed that recycled TDF and
395 switching to AZT for second-line treatment are both safe²².

396 In conclusion, we found that among people who experienced virologic failure during first-line
397 non-dolutegravir-based ART, dolutegravir use for second-line treatment resulted in similar or

398 better retention-in-care and better viral suppression at 12 months follow-up than the previous
399 ritonavir-boosted lopinavir regimen all used in combination with AZT plus XTC. Furthermore,
400 recycled TDF plus XTC with dolutegravir for second-line treatment yielded identical retention-
401 in-care and viral suppression impact as with AZT plus XTC. These findings support the ongoing
402 use of DTG-based second-line regimens in low- and middle-income countries.

403 **Contributors**

404 KA, YS, LL, RJL, KN, NG and JD conceptualised the study. TK, YS, and RvH oversaw data
405 collection. TK, and JvdM managed data curation. KA, YS, TK, JvdM, LL, RvH, NG and JD had
406 full access to the data in the study through their role in eThekwini Municipality, the Health
407 Informatics Directorate, or permissions granted to the Centre for the AIDS Programme of
408 Research in South Africa. KA, JvdM, LL, and JD analysed the data. KA drafted the manuscript.
409 All authors contributed to the interpretation of results, critically reviewed, and approved the final
410 version for submission.

411 **Declaration of interests**

412 RJL is a recipient of research awards from the National Institute of Allergy and Infectious
413 Diseases of the National Institutes of Health under award numbers R01AI152772 and
414 R01AI167699. These awards are for projects relating to the monitoring of HIV drug resistance
415 (focused on dolutegravir resistance) and evaluation of management strategies for people with
416 virological failure on dolutegravir-containing regimens. All other authors declare no competing
417 interests.

418 **Data sharing**

419 We cannot publicly share the data used for this analysis because of the legal and ethical
420 requirements regarding the use of routinely collected clinical data in South Africa. Interested
421 parties can request access to the data from the eThekwini Municipality Health Unit and the South
422 African National Department of Health TB/HIV Information System (contact details obtainable
423 upon request to JD).

424 **Acknowledgements**

425 We thank the eThekwini Municipality Health Unit staff, patients, and primary care clinics. This
426 work was supported by funding from the Africa Oxford Initiative (AfiOx-160), the International
427 Association of Providers of AIDS Care (2021-ISG-Y1-10004), and the Bill & Melinda Gates
428 Foundation (INV-051067). Under the grant conditions of the Bill & Melinda Gates Foundation, a
429 Creative Commons Attribution 4.0 Generic License has already been assigned to the Author
430 Accepted Manuscript version that might arise from this submission. JD, Academic Clinical
431 Lecturer is funded by the NIHR for this research project. The views expressed in this publication

432 are those of the author (s) and not necessarily those of the NIHR, NHS or the UK Department of
433 Health and Social Care.

434 **REFERENCES**

- 435 1. World Health Organisation. Consolidated guidelines on HIV prevention, testing,
436 treatment, service delivery and monitoring: recommendations for a public health approach. 2021.
437 <https://www.who.int/publications/i/item/9789240031593> (accessed 25-May-2023).
- 438 2. World health Organisation. Updated recommendations on first-line and second-line
439 antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant
440 diagnosis of HIV. 2018. <https://www.who.int/publications/i/item/WHO-CDS-HIV-18.51>
441 (accessed 25-May-2023).
- 442 3. Dorward J, Lessells R, Drain PK, et al. Dolutegravir for first-line antiretroviral therapy in
443 low-income and middle-income countries: uncertainties and opportunities for implementation
444 and research. *The Lancet HIV* 2018; **5**(7): e400-e4.
- 445 4. The South African National Department of Health. 2019 ART Clinical Guidelines for the
446 management of HIV in Adults, Pregnancy, Adolescents, Children, Infants and Neonates. In:
447 Health NDo, editor. Pretoria; 2019.
- 448 5. Aboud M, Kaplan R, Lombaard J, et al. Dolutegravir versus ritonavir-boosted lopinavir
449 both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in
450 whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.
451 *Lancet Infect Dis* 2019; **19**(3): 253-64.
- 452 6. Paton NI, Musaazi J, Kityo C, et al. Dolutegravir or Darunavir in Combination with
453 Zidovudine or Tenofovir to Treat HIV. *N Engl J Med* 2021; **385**(4): 330-41.
- 454 7. Zhao Y, Maartens G, Meintjes G. Dolutegravir for second-line treatment: Programmatic
455 implications of new evidence. *South Afr J HIV Med* 2022; **23**(1): 1428.
- 456 8. World Health Organisation. WHO HIV policy adoption and implementation status in
457 countries. 2022. [https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-
458 library/who-hiv-policy-adoption-and-implementation-status-in-
459 countries_nov.pdf?sfvrsn=bb35e6ae_8](https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/who-hiv-policy-adoption-and-implementation-status-in-countries_nov.pdf?sfvrsn=bb35e6ae_8) (accessed 25-May-2023).
- 460 9. Dorward J, Sookrajh Y, Khubone T, et al. Implementation and outcomes of dolutegravir-
461 based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort
462 study. *The Lancet HIV* 2023.

- 463 10. Osler M, Hilderbrand K, Hennessey C, et al. A three-tier framework for monitoring
464 antiretroviral therapy in high HIV burden settings. *Journal of the International AIDS Society*
465 2014; **17**(1): 18908.
- 466 11. South Africa: National Department of Health. Adherence guidelines for HIV, TB and
467 NCDs: Policy and service delivery guidelines for linkage to care, adherence to treatment and
468 retention in care. 2016.
- 469 12. R Core Team. R: A language and environment for statistical computing. 2022.
470 <https://www.R-project.org/>.
- 471 13. Stata Corporation. Stata statistical software release 17. College Station, Texas: Stata
472 Corporation LP; 2017.
- 473 14. Zou GY, Donner A. Extension of the modified Poisson regression model to prospective
474 studies with correlated binary data. *Stat Methods Med Res* 2013; **22**(6): 661-70.
- 475 15. Chirambo L, Valeta M, Banda Kamanga TM, Nyondo-Mipando AL. Factors influencing
476 adherence to antiretroviral treatment among adults accessing care from private health facilities in
477 Malawi. *BMC Public Health* 2019; **19**(1): 1382.
- 478 16. Renju J, Moshabela M, McLean E, et al. 'Side effects' are 'central effects' that challenge
479 retention in HIV treatment programmes in six sub-Saharan African countries: a multicountry
480 qualitative study. *Sex Transm Infect* 2017; **93**(Suppl 3).
- 481 17. Orrell C, Hagins DP, Belonosova E, et al. Fixed-dose combination dolutegravir, abacavir,
482 and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and
483 emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from
484 a randomised, open-label, non-inferiority, phase 3b study. *Lancet HIV* 2017; **4**(12): e536-e46.
- 485 18. Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in
486 antiretroviral-naïve adults with HIV-1 infection: 48 week results from the randomised, double-
487 blind, non-inferiority SPRING-2 study. *Lancet* 2013; **381**(9868): 735-43.
- 488 19. Orkin C, DeJesus E, Khanlou H, et al. Final 192-week efficacy and safety of once-daily
489 darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients
490 in the ARTEMIS trial. *HIV Med* 2013; **14**(1): 49-59.
- 491 20. Spaulding A, Rutherford GW, Siegfried N. Tenofovir or zidovudine in three-drug
492 combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside

- 493 reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve
494 individuals. *Cochrane Database of Systematic Reviews* 2010; (10).
- 495 21. Gallant JE, Dejesus E, Arribas JR, et al. Tenofovir DF, Emtricitabine, and Efavirenz vs.
496 Zidovudine, Lamivudine, and Efavirenz for HIV. *New England Journal of Medicine* 2006;
497 **354**(3): 251-60.
- 498 22. Paton NI, Musaaazi J, Kityo C, et al. Efficacy and safety of dolutegravir or darunavir in
499 combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of
500 HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial,
501 randomised, non. *The Lancet HIV* 2022; **9**(6): e381-e93.
- 502 23. Keene CM, Cassidy T, Zhao Y, et al. Recycling Tenofovir in Second-line Antiretroviral
503 Treatment With Dolutegravir: Outcomes and Viral Load Trajectories to 72 weeks. *J Acquir*
504 *Immune Defic Syndr* 2023; **92**(5): 422-9.
- 505 24. Keene CM, Griesel R, Zhao Y, et al. Virologic efficacy of tenofovir, lamivudine and
506 dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line
507 regimen. *Aids* 2021; **35**(9): 1423-32.
- 508 25. Lloyd B, Mulenga SF, Aggrey Mweemba, Mpanji Siwingwa, Suilanji Sivile, Davies
509 Kampamba, Danielle C. Engamba, Nyuma Mbewe, Henry Phiri, Aaron Shibemba, Bryony
510 Simons, C. William Wester, Lameck Chirwa, Andrew Hill. Dolutegravir with recycled NRTIs is
511 noninferior to PI-based ART: VISEND trial. Conference on Retroviruses and Opportunistic
512 Infections (CROI). Virtual: CROI; 2022.
- 513 26. Gail Matthews MB, Nnekelu Eriobou, Richard Kaplan, N Kumarasamy, Anchalee
514 Avihingsanon, Marcelo H.Losso, Iskander Shah Azwa, Muhammad Karyana, Sounkalo Dao,
515 Mohamed Cisse, Emmanuelle Papot, Simone Jacoby, Jolie Hutchison, Matthew G.Law. D2EFT:
516 dolutegravir and darunavir evaluation in adults failing first-line HIV therapy. Conference on
517 Retroviruses and Opportunistic Infections (CROI). Seattle, Washington,USA: CROI; 2023.
- 518 27. Sigaloff KC, Hamers RL, Wallis CL, et al. Second-line antiretroviral treatment
519 successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-
520 Saharan Africa. *J Infect Dis* 2012; **205**(11): 1739-44.
- 521 28. Segeral O, Nerrienet E, Neth S, et al. Positive Virological Outcomes of HIV-Infected
522 Patients on Protease Inhibitor-Based Second-Line Regimen in Cambodia: The ANRS 12276
523 2PICAM Study. *Front Public Health* 2018; **6**: 63.

- 524 29. Van Onzenoort HAW, Menger FE, Neef C, et al. Participation in a Clinical Trial
525 Enhances Adherence and Persistence to Treatment. *Hypertension* 2011; **58**(4): 573-8.
- 526 30. Chammartin F, Dao Ostinelli CH, Anastos K, et al. International epidemiology databases
527 to evaluate AIDS (IeDEA) in sub-Saharan Africa, 2012–2019. *BMJ Open* 2020; **10**(5): e035246.
- 528

529 **Figures**

530 **Figure 1.** Flow diagram of participants receiving care at 59 clinics in South Africa. ART = Antiretroviral treatment, AZT = Zidovudine, DTG = Dolutegravir, EFV = Efavirenz,
531 LVP/r = Lopinavir-ritonavir, ml = Milliliter, NVP = Nevirapine, PLHIV = People living with HIV, TDF = Tenofovir disoproxil fumarate, XTC = Emtricitabine or Lamivudine.

532

533

534

535




Table 1. Baseline characteristics of PLHIV who were switched to second-line ART after virologic failure while receiving EFV^a or NVP-based^a first-line treatment

Variable	Overall, N = 1214	Second-line ART regimen combination		
		AZT/XTC/LPV/r, N = 689	AZT/XTC/DTG, N = 217	TDF/XTC/DTG, N = 308
Age in years, median (IQR)	36 (30, 42)	35 (30, 41)	37 (32, 43)	36 (30, 43)
Age in years				
15-24	91 (7.5%)	54 (7.8%)	10 (4.6%)	27 (8.8%)
25-34	429 (35.3%)	255 (37.0%)	71 (32.7%)	103 (33.4%)
35-44	479 (39.5%)	274 (39.8%)	88 (40.6%)	117 (38.0%)
45+	215 (17.7%)	106 (15.4%)	48 (22.1%)	61 (19.8%)
Gender				
Male	485 (40.0%)	229 (33.2%)	109 (50.2%)	147 (47.7%)
Female	729 (60.0%)	460 (66.8%)	108 (49.8%)	161 (52.3%)
Known pregnant (females only)	14 (1.9%)	10 (2.2%)	1 (0.9%)	3 (1.9%)
Known tuberculosis	24 (2.0%)	14 (2.0%)	6 (2.8%)	4 (1.3%)
Baseline time-period of second-line switch				
Dec19-Feb20	224 (18.5%)	190 (27.6%)	7 (3.2%)	27 (8.8%)
Mar20-May20	324 (26.7%)	204 (29.6%)	54 (24.9%)	66 (21.4%)
Jun20-Aug20	370 (30.5%)	165 (23.9%)	70 (32.3%)	135 (43.8%)
Sep20-Nov20	296 (24.4%)	130 (18.9%)	86 (39.6%)	80 (26.0%)
Recent viral load (copies/ml) before second-line switch				
1,000 to <10,000	495 (40.8%)	260 (37.7%)	80 (36.9%)	155 (50.3%)
10,000 to <50,000	386 (31.8%)	220 (31.9%)	70 (32.3%)	96 (31.2%)
50000 to <100,000	133 (11.0%)	80 (11.6%)	32 (14.7%)	21 (6.8%)
100,000+	200 (16.5%)	129 (18.7%)	35 (16.1%)	36 (11.7%)
Days since recent viral load (copies/ml) before second-line switch, median (IQR)	47 (26, 92)	50 (28, 95)	49 (28, 102)	34 (0, 79)
Days since first high viral load (copies/ml) before second-line switch, median (IQR)	195 (140, 276)	196 (139, 282)	198 (141, 300)	190 (140, 252)
Recent CD4 count (cells/μl)				
≤ 200	437 (36.0%)	264 (38.3%)	94 (43.3%)	79 (25.6%)
201–350	307 (25.3%)	163 (23.7%)	51 (23.5%)	93 (30.2%)
351–500	174 (14.3%)	90 (13.1%)	25 (11.5%)	59 (19.2%)
> 500	133 (11.0%)	72 (10.4%)	19 (8.8%)	42 (13.6%)
Missing	163 (13.4%)	100 (14.5%)	28 (12.9%)	35 (11.4%)
Days since recent CD4 count (cells/μl), median (IQR)	400 (105, 923)	402 (104, 928)	273 (54, 914)	434 (168, 914)
Previous first-line ART before second-line switch				
TDF/XTC/EFV	1,198 (98.7%)	681 (98.8%)	215 (99.1%)	302 (98.1%)
TDF/XTC/NVP	16 (1.3%)	8 (1.2%)	2 (0.9%)	6 (1.9%)
ART pick-up point at baseline				
Main clinic	1,192 (98.2%)	681 (98.8%)	215 (99.1%)	296 (96.1%)
CCMDD ^b	22 (1.8%)	8 (1.2%)	2 (0.9%)	12 (3.9%)
Years since ART initiation, median (IQR)	2.9 (1.5, 5.5)	2.9 (1.5, 5.5)	3.5 (1.5, 6.2)	2.6 (1.4, 4.7)
Years since ART initiation				
< 2 year	446 (36.7%)	252 (36.6%)	72 (33.2%)	122 (39.6%)
≥ 2 years	768 (63.3%)	437 (63.4%)	145 (66.8%)	186 (60.4%)

Data are n (%) or median (IQR). All percentages were calculated with the total number in the respective column headers as the denominators except otherwise stated. ^aEfavirenz or nevirapine based first-line regimens were in combination with TDF plus XTC. ^bCCMDD included external or internal pickup points, spaced fast lanes and adherence clubs. ART = Antiretroviral treatment, AZT = Zidovudine, DTG = Dolutegravir, EFV = Efavirenz, CCMDD = Central Chronic Medicines Dispensing and Distribution, IQR = Interquartile range, LPV/r = Lopinavir-ritonavir, μl = Microliter, ml = Milliliter, NVP = Nevirapine, PLHIV = People living with HIV, TDF = Tenofovir disoproxil fumarate, XTC = Emtricitabine or Lamivudine.

medRxiv preprint doi: <https://doi.org/10.1101/2023.07.07.23292347>; this version posted July 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Table 2. Follow-up outcomes in PLHIV who were switched to second-line ART after virologic failure while receiving EFV^a or NVP-based^a first-line treatment

Variable	Overall, N = 1214	Second-line ART regimen combination		
		AZT/XTC/LPV/r, N = 689	AZT/XTC/DTG, N = 217	TDF/XTC/DTG, N = 308
Second-line regimen-change within 12 months	121 (10.0%)	59 (8.6%)	21 (9.7%)	41 (13.3%)
Days to second-line regimen-change within 12 months, median (IQR)	158 (84, 234)	146 (74, 204)	182 (97, 231)	160 (84, 253)
Second-line regimen changed to (of participants who changed regimen within 12 months)				
AZT/XTC/LPV/r	17 (14.0%)	0 (0.0%)	4 (19.0%)	13 (31.7%)
AZT/XTC/DTG	35 (28.9%)	16 (27.1%)	0 (0.0%)	19 (46.3%)
TDF/XTC/DTG	26 (21.5%)	12 (20.3%)	14 (66.7%)	0 (0.0%)
Other	43 (35.5%)	31 (52.5%)	3 (14.3%)	9 (22.0%)
Follow-up outcome at 12 months				
Lost to follow-up	177 (14.6%)	112 (16.3%)	20 (9.2%)	45 (14.6%)
Died	16 (1.3%)	9 (1.3%)	4 (1.8%)	3 (1.0%)
Transferred out to another clinic	80 (6.6%)	50 (7.3%)	7 (3.2%)	23 (7.5%)
Retained in care	941 (77.5%)	518 (75.2%)	186 (85.7%)	237 (76.9%)
Viral load done at 12 months (of participants retained in care at 12 months)	799 (84.9%)	448 (86.5%)	150 (80.6%)	201 (84.8%)
Days to viral load (copies/ml) at 12 months (of participants retained in care at 12 months), median (IQR)	357 (293, 418)	362 (299, 419)	342 (277, 394)	357 (296, 426)
Viral load (copies/ml) at 12 months (of participants retained in care at 12 months)				
<50	420 (52.6%)	209 (46.7%)	89 (59.3%)	122 (60.7%)
50-199	102 (12.8%)	61 (13.6%)	20 (13.3%)	21 (10.4%)
200-999	75 (9.4%)	41 (9.2%)	20 (13.3%)	14 (7.0%)
1000+	202 (25.3%)	137 (30.6%)	21 (14.0%)	44 (21.9%)

Data are n (%) or median (IQR). All percentages were calculated with the total number in the respective column headers as the denominators except otherwise stated. ^aEfavirenz or nevirapine based first-line regimens were in combination with TDF plus XTC. ART = Antiretroviral treatment, AZT = Zidovudine, DTG = Dolutegravir, EFV = Efavirenz, IQR = Interquartile range, LPV/r = Lopinavir-ritonavir, µl = Microliter, ml = Milliliter, NVP = Nevirapine, PLHIV = People living with HIV, TDF = Tenofovir disoproxil fumarate, XTC = Emtricitabine or Lamivudine.

Table 3. Univariable and multivariable Poisson regression models of factors associated with retention-in-care at 12 months in PLHIV who were switched to second-line ART after virologic failure while receiving EFV^a or NVP-based^a first-line treatment (N = 1214)

Variable	Level	Retention-in-care at 12 months n/N (%)	Unadjusted RR (95% CI)	P value	Adjusted RR ^b (95% CI)	P value
Second-line regimen	AZT/XTC/LPV/r	518/689 (75.2)	1	-	1	-
	AZT/XTC/DTG	186/217 (85.7)	1.14 (1.03-1.27)	0.013	1.14 (1.03-1.27)	0.012
	TDF/XTC/DTG	237/308 (76.9)	1.02 (0.94-1.11)	0.630	1.01 (0.94-1.10)	0.733
Age at baseline	15-24	67/91 (73.6)	1	-	1	-
	25-34	323/429 (75.3)	1.03 (0.90-1.17)	0.714	1.03 (0.90-1.17)	0.714
	35-44	377/479 (78.7)	1.07 (0.94-1.22)	0.307	1.07 (0.95-1.22)	0.274
	45+	174/215 (80.9)	1.10 (0.98-1.25)	0.113	1.10 (0.97-1.24)	0.135
Gender	Male	373/485 (76.9)	1	-	1	-
	Female	568/729 (77.9)	1.01 (0.95-1.08)	0.673	1.03 (0.98-1.10)	0.258
Known tuberculosis status at baseline	No	925/1190 (77.7)	1	-	1	-
	Yes	16/24 (66.7)	0.85 (0.63-1.15)	0.299	0.86 (0.64-1.15)	0.312
Recent viral load (copies/ml) at baseline	1000 to < 10000	399/495 (80.6)	1	-	1	-
	≥ 10000	542/719 (75.4)	0.93 (0.88-0.99)	0.030	0.94 (0.88-1.00)	0.042
Recent CD4 count (cells/μl) at baseline	≤ 200	338/437 (77.3)	1	-	-	-
	201–350	235/307 (76.5)	0.99 (0.91-1.08)	0.832	-	-
	351–500	128/174 (73.6)	0.95 (0.86-1.05)	0.327	-	-
	> 500	106/133 (79.7)	1.03 (0.92-1.15)	0.585	-	-
	Missing	134/163 (82.2)	1.08 (0.99-1.17)	0.067	-	-
Years on ART at baseline	< 2 year	335/446 (75.1)	1	-	-	-
	≥ 2 years	606/768 (78.9)	1.05 (0.97-1.13)	0.207	-	-

Data are n/N (%), unless otherwise stated. ^aEfavirenz or nevirapine based first-line regimens were in combination with TDF plus XTC. ^bThe primary exposure effect (retention-in-care at 12 months) is adjusted for all other variables in the table as potential confounders except CD4 count and Years on ART at baseline. ART = Antiretroviral treatment, AZT = Zidovudine, DTG = Dolutegravir, EFV = Efavirenz, LVP/r = Lopinavir-ritonavir, μl = Microliter, ml = Milliliter, NVP = Nevirapine, PLHIV = People living with HIV, RR = Risk ratio, TDF = Tenofovir disoproxil fumarate, XTC = Emtricitabine or Lamivudine.

Table 4. Univariable and multivariable Poisson regression models of factors associated with viral suppression (< 50 copies/ml) at 12 months in PLHIV who were switched to second-line ART after virologic failure while receiving EFV^a or NVP-based^a first-line treatment (N = 799)

Variable	Level	Viral load at 12 months < 50 copies/ml n/N (%)	Unadjusted RR (95% CI)	P value	Adjusted RR ^b (95% CI)	P value
Second-line regimen	AZT/XTC/LPV/r	209/448 (46.7)	1	-	1	-
	AZT/XTC/DTG	89/150 (59.3)	1.22 (1.03-1.46)	0.022	1.25 (1.06-1.47)	0.009
	TDF/XTC/DTG	122/201 (60.7)	1.31 (1.15-1.49)	<0.001	1.30 (1.14-1.48)	<0.001
Age at baseline	15-24	21/56 (37.5)	1	-	1	-
	25-34	153/282 (54.3)	1.46 (0.99-2.14)	0.056	1.50 (1.01-2.21)	0.043
	35-44	159/308 (51.6)	1.37 (0.91-2.06)	0.127	1.45 (0.96-2.17)	0.075
	45+	87/153 (56.9)	1.55 (1.06-2.27)	0.024	1.58 (1.07-2.33)	0.022
Gender	Male	156/313 (49.8)	1	-	1	-
	Female	264/486 (54.3)	1.10 (0.98-1.23)	0.111	1.12 (1.00-1.25)	0.053
Known tuberculosis status at baseline	No	415/784 (52.9)	1	-	1	-
	Yes	5/15 (33.3)	0.66 (0.30-1.45)	0.302	0.69 (0.32-1.48)	0.337
Recent viral load (copies/ml) at baseline	1000 to < 10000	198/337 (58.8)	1	-	1	-
	≥ 10000	222/462 (48.1)	0.83 (0.73-0.93)	0.002	0.85 (0.76-0.96)	0.008
Recent CD4 count (cells/μl) at baseline	≤ 200	153/292 (52.4)	1	-	-	-
	201–350	96/194 (49.5)	0.95 (0.81-1.11)	0.492	-	-
	351–500	66/108 (61.1)	1.14 (0.94-1.39)	0.180	-	-
	> 500	42/90 (46.7)	0.90 (0.66-1.23)	0.514	-	-
	Missing	63/115 (54.8)	1.04 (0.83-1.31)	0.730	-	-
Years on ART at baseline	< 2 year	156/286 (54.5)	1	-	-	-
	≥ 2 years	264/513 (51.5)	0.95 (0.82-1.10)	0.479	-	-

Data are n/N (%), unless otherwise stated. ^aEfavirenz or nevirapine based first-line regimens were in combination with TDF plus XTC. ^bThe primary exposure effect (viral suppression at 12 months) is adjusted for all other variables in the table as potential confounders. ART = Antiretroviral treatment, AZT = Zidovudine, DTG = Dolutegravir, EFV = Efavirenz, LPV/r = Lopinavir-ritonavir, μl = Microliter, ml = Milliliter, NVP = Nevirapine, PLHIV = People living with HIV, RR = Risk ratio, TDF = Tenofovir disoproxil fumarate, XTC = Emtricitabine or Lamivudine.